Recently, Yamamoto and colleagues showed that olaparib-resistant ovarian cancer cells upregulate Wnt3A and that forced activation of the canonical Wnt/β-catenin pathway resulting in resistance to both olaparib and rucaparib (28). This evidence concerns the gene WNT3A and ovarian carcinoma.